Skip to main content
. Author manuscript; available in PMC: 2009 Sep 29.
Published in final edited form as: J Natl Cancer Inst. 2008 Apr 29;100(9):649–662. doi: 10.1093/jnci/djn113

Figure 1.

Figure 1

Bortezomib (Bzb)-induced sensitization of renal and mammary mouse tumors to tumor necrosis factor–related apoptosis-inducing ligand (TRAIL). A) Renca-FLAG, Renca-FLIP, and 4T1 tumor cells were untreated or pretreated with 20 nM Bzb for 3 hours. Cells were then treated with soluble recombinant mouse TRAIL (1 µg/mL) or medium. B) The cells were treated the same way except that instead of TRAIL they were treated with protein A–bound immobilized TRAIL receptor agonist monoclonal antibody MD5-1 (5 µg/mL). Cell viability was determined 18 hours later using 3-[4,5-dimethyiazol-2-yl-5]-[3-carboxymethyloxyphenyl]-2-[4-sulfophenyl]-2H tetrazolium assay. Percent decrease in cell number of treated cells compared with untreated cells is shown as means and 95% confidence intervals (n = 3) from one representative experiment of four (A) and three (B) independent experiments. *P < .001 (analysis of variance, two-sided) with respect to single agents.